英克西兰治疗策略在高胆固醇血症中的VICTORION-Difference试验
VICTORION-Difference是一项4期双盲安慰剂对照随机试验,纳入1770例高或极高心血管风险的高胆固醇血症成人,比较英克西兰联合个体化优化降脂治疗与单纯优化降脂治疗。结果显示英克西兰组第90天LDL-C达标率84.9%显著高于对照组31.0%,第360天LDL-C平均降幅59.5%对24.3%,且肌肉相关不良事件更少。
要点
- 英克西兰联合优化降脂显著提高LDL-C达标率:84.9%对31.0%。
- 第360天LDL-C平均降幅英克西兰组59.5%,对照组24.3%。
- 英克西兰组肌肉相关不良事件报告率更低:11.9%对19.2%。
核心结论
- 基于英克西兰的治疗策略在LDL-C达标和持续降低方面优于个体化优化降脂治疗,且肌肉相关不良事件更少。
研究设计与样本
- VICTORION-Difference为4期双盲、安慰剂对照随机临床试验,纳入高或极高心血管风险的高胆固醇血症成人1770例,平均年龄63.7岁,按1:1随机接受英克西兰钠300mg皮下注射(相当于284mg英克西兰)或安慰剂,联合个体化优化降脂治疗(包括开放标签瑞舒伐他汀上调至个体LDL-C目标或最大耐受剂量)。
主要发现
- 第90天英克西兰组LDL-C达标率84.9%,对照组31.0%,OR 12.09,P<0.001。
- 第360天LDL-C自基线平均降幅英克西兰组-59.5%,对照组-24.3%,最小二乘均值治疗差异-35.14%,P<0.001。
- 英克西兰组肌肉相关不良事件报告率11.9%,对照组19.2%,OR 0.57,P<0.001。
- 简表疼痛量表疼痛严重程度和干扰评分平均降低英克西兰组优于对照组,LSMTD分别为-0.11(P=0.039)和-0.11(P=0.029)。
- 未发现新的安全性问题。
临床怎么用
- 对于高或极高心血管风险的高胆固醇血症患者,可考虑在优化降脂治疗基础上加用英克西兰以更早、更持续地实现LDL-C目标并减少肌肉相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular (CV) disease development and progression. The European Society of Cardiology guidelines recommend combination treatment to achieve CV risk-based LDL-C treatment goals. Inclisiran, a small interfering ribonucleic acid (siRNA) that targets hepatic proprotein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA, can provide sustained and effective LDL-C reduction. METHODS: VICTORION-Difference, a phase 4 double-blind, placebo-controlled randomized clinical trial included adults with hypercholesterolaemia at high- or very high CV risk. Participants were randomized 1:1 to receive inclisiran sodium (300 mg subcutaneous injections; equivalent to 284 mg inclisiran) or placebo together with individually optimized lipid-lowering therapy (ioLLT), including up-titration with rosuvastatin (open-label) until either their individual LDL-C goal or maximally tolerated statin dose (open-label rosuvastatin) was achieved. The primary objective was assessment of LDL-C goal achievement at Day 90. Key secondary objectives were muscle-related adverse events (MRAEs) and mean LDL-C reduction. Overall, 1770 individuals (mean age, 63.7 years) were randomized to receive inclisiran (n = 898) or ioLLT (n = 872). At Day 90, a significantly higher proportion of participants receiving inclisiran vs. ioLLT achieved their individual LDL-C goals [84.9% vs 31.0%; odds ratio (OR) 12.09, P < .001]. The mean percentage reduction in LDL-C from baseline to Day 360 was -59.5% and -24.3% in the inclisiran and ioLLT arms, respectively [least squares mean treatment difference (LSMTD) = -35.14%, P < .001]. Fewer participants receiving inclisiran vs ioLLT reported a MRAE (11.9% vs 19.2%; OR 0.57, P < .001). The mean reduction in Short Form-Brief Pain Inventory pain severity and interference scores favoured inclisiran over ioLLT (LSMTD = -0.11, P = .039; LSMTD = -0.11, P = .029, respectively). No new safety concerns were identified. RESULTS: Overall, 1770 individuals (mean age, 63.7 years) were randomized to receive inclisiran (n=898) or ioLLT (n=872). At Day 90, a significantly higher proportion of participants receiving inclisiran vs. ioLLT achieved their individual LDL-C goals (84.9% vs. 31.0%; odds ratio [OR] 12.09, p<0.001). The mean percentage reduction in LDL-C from baseline to Day 360 was -59.5% and -24.3% in the inclisiran and ioLLT arms, respectively (least squares mean treatment difference [LSMTD]=-35.14%, p<0.001). Fewer participants receiving inclisiran vs. ioLLT reported a MRAE (11.9% vs. 19.2%; OR 0.57, p<0.001). The mean reduction in Short Form-Brief Pain Inventory pain severity and interference scores favoured inclisiran over ioLLT (LSMTD=-0.11, p=0.039; LSMTD=-0.11, p=0.029, respectively). No new safety concerns were identified. CONCLUSIONS: An inclisiran-based treatment strategy was superior to ioLLT in LDL-C goal achievement, delivering early and sustained LDL-C reduction, with fewer MRAEs in individuals with hypercholesterolaemia.
引用
- Landmesser U, Laufs U, Schatz U, et al. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial. Eur Heart J. 2026. PMID: 40884558. doi:10.1093/eurheartj/ehaf685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。